Company launches clinical study of AI-designed oral formulation following MHRA approval, marking a major milestone in AI-driven drug development.
On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25
The finance leader and investment banking veteran to steer global financial strategy, investor relations, and growth initiatives
The acquisition marks Anupam Rasayan’s strategic entry into the pharmaceutical formulations segment
If approved, TEV-‘749 would mark a shift toward long-acting care aimed at improving treatment adherence in real-world settings
The approval was granted by Agenzia Italiana del Farmaco
The new CRS offering is delivered from WACKER’s Biotechnology Center in Munich
Net profit stood at Rs. 921 crore for the quarter, while Europe revenues surged 30.2% YoY to Rs. 2,795 crore
Q4FY26 revenue rises 13.6% to Rs. 14,560 crore; quarterly net profit jumps 26.2% to Rs. 2,714 crore driven by India business and Innovative Medicines growth
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
